Your Cart ( 2 Items )

• An Update on the Long-Term Safety Experience of Ustekinumab: Results From the Psoriasis Clinical Development Program With up to Four Years of Follow-Up
  March 2012 | Volume 11 | Issue 3 | Original Article | 300 | Copyright © March 2012
  

  Kristian Reich MD,^a Kim A. Papp MD,^b Christopher E. M. Griffiths MD,^c Philippe O. Szapary MD,^d Newman Yeilding MD,^d Yasmine Wasfi MD,^d Elyssa Ott MPH,^d Ming-Chun Hsu PhD,^d Mark Lebwohl MD,^e Kenneth B. Gordon MD,^f on behalf of the PHOENIX 1, PHOENIX 2, and ACCEPT investigators

  ^aDermatologikum Hamburg, Hamburg, Germany ^bProbity Medical Research, Waterloo, Ontario, Canada ^cUniversity of Manchester, Manchester Academic Health Science Centre, Manchester, UK ^dJanssen Research & Development, LLC, Spring House, PA ^eMount Sinai Medical Center, New York, NY ^fNorthwestern University, Feinberg School of Medicine, Chicago, IL

  
  You will have 48 hours to download the full-text PDF

  Price

  24.95

  Term

  48 Hrs
• Imiquimod 2.5% and 3.75% for the Treatment of Actinic Keratoses: Two Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies
  November 2013 | Volume 12 | Issue 11 | Original Article | 1278 | Copyright © November 2013
  Neil Swanson MD^a, Christina Cognata Smith MD^b, Mandeep Kaur MD^b, and Gary Goldenberg M^c
  You will have 48 hours to download the full-text PDF

  Price

  24.95

  Term

  48 Hrs